Pulmonary fibrosis secondary to COVID-19: a narrative review

Página do item simplificado
dc.contributor.authorTanni, Suzana Erico [UNESP]
dc.contributor.authorFabro, Alexandre Todorovic
dc.contributor.authorde Albuquerque, André
dc.contributor.authorFerreira, Eloara Vieira Machado
dc.contributor.authorVerrastro, Carlos Gustavo Yuji
dc.contributor.authorSawamura, Márcio Valente Yamada
dc.contributor.authorRibeiro, Sergio Marrone [UNESP]
dc.contributor.authorBaldi, Bruno Guedes
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.date.accessioned2021-06-25T10:59:13Z
dc.date.available2021-06-25T10:59:13Z
dc.date.issued2021-01-01
dc.description.abstractIntroduction: Coronavirus disease 2019 (COVID-19) is still increasing worldwide, and as a result, the number of patients with pulmonary fibrosis secondary to COVID-19 will expand over time. Risk factors, histopathological characterization, pathophysiology, prevalence, and management of post-COVID-19 pulmonary fibrosis are poorly understood, and few studies have addressed these issues.Areas covered:This article reviews the current evidence regarding post-COVID-19 pulmonary fibrosis, with an emphasis on the potential risk factors, histopathology, pathophysiology, functional and tomographic features, and potential therapeutic modalities. A search on the issue was performed in the MEDLINE, Embase, and SciELO databases and the Cochrane library between 1 December 2019, and 25 January 2021. Studies were reviewed and relevant topics were incorporated into this narrative review. Expert opinion: Pulmonary sequelae may occur secondary to COVID-19, which needs to be included as a potential etiology in the current differential diagnosis of pulmonary fibrosis. Therefore, serial clinical, tomographic, and functional screening for pulmonary fibrosis is recommended after COVID-19, mainly in patients with pulmonary involvement in the acute phase of the disease. Further studies are necessary to determine the risk factors, markers, pathophysiology, and appropriate management of post-COVID-19 pulmonary fibrosis.en
dc.description.affiliationDivision of Internal Medicine of Botucatu Medical School São Paulo State University-UNESP
dc.description.affiliationDepartment of Pathology and Legal Medicine Ribeirão Preto Medical School University of São Paulo
dc.description.affiliationDivisão De Pneumologia Instituto Do Coração (Incor) Hospital Das Clínicas HCFMUSP Faculdade De Medicina Universidade De São Paulo
dc.description.affiliationPulmonology Division Paulista Medical School Federal University of São Paulo
dc.description.affiliationRadiology Division Paulista Medical School Federal University of São Paulo
dc.description.affiliationInstituto De Radiologia Hospital Das Clínicas HCFMUSP Faculdade De Medicina Universidade De São Paulo
dc.description.affiliationDepartment of Radiology Botucatu Medical School São Paulo State University-UNESP
dc.description.affiliationUnespDivision of Internal Medicine of Botucatu Medical School São Paulo State University-UNESP
dc.description.affiliationUnespDepartment of Radiology Botucatu Medical School São Paulo State University-UNESP
dc.identifierhttp://dx.doi.org/10.1080/17476348.2021.1916472
dc.identifier.citationExpert Review of Respiratory Medicine.
dc.identifier.doi10.1080/17476348.2021.1916472
dc.identifier.issn1747-6356
dc.identifier.issn1747-6348
dc.identifier.scopus2-s2.0-85105121341
dc.identifier.urihttp://hdl.handle.net/11449/207680
dc.language.isoeng
dc.relation.ispartofExpert Review of Respiratory Medicine
dc.sourceScopus
dc.subjectCoronavirus
dc.subjectcovid-19
dc.subjectct-scan
dc.subjectinterstitial lung disease
dc.subjectlung function
dc.subjectpost-covid-19
dc.subjectpulmonary fibrosis
dc.subjectpulmonary sequelae
dc.titlePulmonary fibrosis secondary to COVID-19: a narrative reviewen
dc.typeResenha

Arquivos

Coleções

Artigos - Clínica Médica - FMB
Artigos - Reprodução Animal e Radiologia Veterinária - FMVZ